

## C. 研究結果

亜型分類は、A/H1N1 59、A/H3N2 10、亜型不明 14、陰性 78 であった。成人 23 名の迅速診断キット A 陽性者の唾液を用いた SGNP-RT-PCR 法の結果はすべて陽性であった。一方、小児の鼻腔ぬぐい液と唾液の SGNP-RT-PCR 法の結果を比較すると、鼻腔ぬぐい液陽性で唾液が陰性であった偽陰性率は 32% (7/22) であった (表1)。偽陰性の出現頻度は、患者年齢や検体採取が綿棒であったかどうかとは関連がなかった。

成人患者の唾液におけるウイルス排泄期間を図1に示す。23 名中 8 名で発症 7 日以後もウイルスが検出されており、10 日以上陽性が続いた患者が 4 名みられた。長期排泄者は、H3N2 に多い傾向があった。

## D. 考察

唾液検体を用いた SGNP-RT-PCR 法は成人では有用であり、鼻腔ぬぐい液に比べて検体採取がきわめて容易であることから、臨床応用が可能と考えられる。小児でも年齢によらず唾液から検出可能であることがわかったが、偽陰性率が比較的高く、唾液採取法や検体の処理などに工夫が必要と考えられる。

インフルエンザウイルス排泄期間は、従来の RT-PCR 法で検討された報告ではおおむね 7 日以内であったが、唾液検体を用いた SGNP-RT-PCR 法では明らかに長かった。この原因は本法の高感度を反映していると思われるが、H3N2 の排泄期間が H1N1 (2009) に比べて長い傾向があった原因は不明である。

本法は、高感度であるがゆえに、一般診療では不顕性感染やごく軽度の症状の患者でも陽性になる可能性がある。感染初期からの早期治療が必要となる基礎疾患のあるハイリスク

患者や院内感染対策上早期隔離が必要となる入院患者での早期診断では、本法の有用性がさらに高まると考えられる。

## E. 結論

成人の唾液検体を用いた SGNP-RT-PCR 法は、インフルエンザウイルスの検出に有用であり、今後の臨床応用が期待される。小児の検体では偽陰性検体が少なからずみられ、今後の工夫が必要である。

## F. 研究発表

### 1. 論文発表

- 1) Ueno K, Nishi J, Imuta N, Tokuda K, Kawano Y. Presence of multiple copies of capsulation loci in invasive *Haemophilus influenzae* type b (Hib) strains in Japan before introduction of the Hib conjugate vaccine. *Microb Immunol* 2010;54(3):160-163
- 2) Tokuda K, Nishi J, Imuta N, Fujiyama R, Kamenosono A, Manago K, Yoshifumi K. Characterization of typical and atypical enteroaggregative *Escherichia coli* in Kagoshima, Japan: biofilm formation and acid resistance. *Microb Immunol* 2010: 54(6):320-329

### 2. 学会発表


- 1) 井之上寿美, 丸山慎介, 江口太助, 西 順一郎, 益田君教, 立元千帆, 石川珠代, 山元公恵, 鮫島幸二, 池田琢哉. 皮下気腫を伴ったパンデミックインフルエンザ H1N1 肺炎の女児例. 第 15 回鹿児島小児感染症研究会 鹿児島 2010.9.17

G. 知的財産権の出願・登録状況  
特になし。

表 1 小児の鼻腔ぬぐい液と唾液の SGNP-RT-PCR 結果の比較

	鼻腔ぬぐい液	
	SGNP-RT-PCR +	SGNP-RT-PCR -
唾液 SGNP-RT-PCR +	15	1
唾液 SGNP-RT-PCR -	7	5

図 1 成人唾液中のインフルエンザウイルス排泄の推移



上段を陽性、下段を陰性として、同一患者の検体を線で示し、インフルエンザウイルス排泄状況の推移を示す (n=23)。破線は H1N1(2009)、実線は H3N2 が検出された患者を示す。

Ⅲ. 研究成果の刊行に関する一覧表

研究成果の刊行に関する一覧

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
Ando, H., <u>Ishida, H.</u> and Kiso, M.	Renewed synthetic approach to gangliosides exploiting versatile and powerful synthetic units	F. Minoru	Methods In Enzymology, Glycomics	Elsevier	Amsterdam, Boston, Heidelberg, London, New York, Oxford, Paris, San Diego, San Francisco, Singapore, Sydney, Tokyo	2010	522-540
<u>石田秀治</u> 木曾真	「グルコシル化を阻害するための化学的ツール」「バイオテクノロジーと医薬品産業における糖鎖」	鈴木康夫 木全弘治	コールドスプリングハーバー糖鎖生物学第2版	丸善	東京	2010	597-619
岡本隆之 <u>梶川浩太郎</u>	プラズモニクス基礎と応用		プラズモニクス基礎と応用	株式会社講談社	東京	2010	総ページ数 263

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
J.P. Yang, R. Yoshida, Y. Kariya, X. Zhang, S. Hashiguchi, T. Nakashima, <u>Y. Suda</u> , A. Takada, Y. Ito and K. Sugimura	Characterization of human single-chain antibodies against highly pathogenic avian influenza H5N1 viruses: mimotope and neutralizing activity	<i>J. Biochem.</i>	148(4)	507-515	2010
E. Wijelath, M. Namekata, J. Murray, M. Furuyashiki, S. Zhang, D. Coan, M. Wakao, R. B. Harris, <u>Y. Suda</u> , L. Wang, M. Sobel	Multiple Mechanisms for Exogenous Heparin Modulation of Vascular Endothelial Growth Factor Activity	<i>J. Cell. Biochem.</i>	111(2)	461-468	2010
H. Kariya, Y. Yoshihara, Y. Nakao, N. Sakurai, M. Ueno, M. Hashimoto, <u>Y. Suda</u>	Carboxymethyl-chitin promotes chondrogenesis by inducing the production of growth factors from immune cells	<i>J. Biomed. Mater. Res. A</i>	94A(4)	1034-1041	2010



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
A. Saito, M. Wakao, H. Deguchi, A. Mawatari, M. Sobel, <u>Y. Suda</u>	Toward the assembly of heparin and heparin sulfate oligosaccharide libraries: efficient synthesis of uronic acid and disaccharide building blocks	<i>Tetrahedron</i>	66	3951-3962	2010
<u>Okuno T</u> , Hooper LC, Ursea R, Smith J, Nussenblatt R, Hooks JJ, Hayashi K	Role of Human Herpes Virus 6 in Corneal Inflammation Alone or With Human Herpesviruses	<i>Cornea</i>	30	204-207	2011
Sadagopan, M., Moriya, S., Suzuki, T., Miyagi, T., <u>Ishida, H.</u> and Kiso, M.	Use of structure-based virtual screening in the investigation of novel human sialidase inhibitors	<i>Med. Chem. Res.</i>	19	1273-1286	2010
Nakashima, S., Ando, H., Imamura, A., Yuki, N., <u>Ishida, H.</u> and Kiso, M.	A First Total Synthesis of a Hybrid-Type Ganglioside Associated with Amyotrophic Lateral Sclerosis-Like Disorder	<i>Chem. Eur. J.</i>	17	588-597	2011
Abdu-Allah, H.H.M., Watanabe, K., Completo, G.C., Sadagopan, M., Hayashizaki, K., Takaku, C., Tamanaka, T., Takematsu, H., Kozutsumi, Y., Paulson, J.C., Tsubata, T., Ando, H., <u>Ishida, H.</u> and Kiso, M.	CD22-Antagonists with nanomolar potency: The synergistic effect of hydrophobic groups at C-2 and C-9 of sialic acid scaffold	<i>Bioorg. Med. Chem.</i>	19	1966-1971	2011
Tamai, H., Ando, H., Tanaka, H., Hosoda-Yabe, R., Yabe, T., <u>Ishida, H.</u> and Kiso, M.	The Total Synthesis of the Neurogenic Ganglioside LLG-3 Isolated from the Starfish <i>Linckia laevigata</i>	<i>Angew. Chem. Int. Ed. Engl.</i>	50	2330-2333	2011
Kozako T, Akimoto M, Toji S, White Y, Suzuki S, Arima T, Suruga Y, Matsushita K, Shimeno H, Soeda S, Kubota R, Izumo S, Uozumi K, <u>Arima N</u>	Target Epitopes of HTLV-1 Recognized by Class I MHC-Restricted Cytotoxic T Lymphocytes in Patients With Myelopathy and Spastic Paraparesis and Infected Patients With Autoimmune Disorders	<i>Journal of Medical Virology</i>	83	501-509	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Kozako T, Hirata S, Shimizu Y, Satoh Y, Yoshimitsu M, White Y, Lemonnier F, Shimeno H, Soeda S, <u>Arima N</u>	Oligomannose-coated liposomes efficiently induce human T-cell leukemia virus-1-specific cytotoxic T lymphocytes without adjuvant	<i>FEBS Journal</i>	278	1358-1366	2011
Nakamura M, Aoyama A, Salim MTA, <u>Okamoto M</u> , <u>Baba M</u> , Miyachi H, Hashimoto Y, Aoyama H	Structural development studies of anti-hepatitis C virus agents with a phenanthridinone skeleton	<i>Bioorg. Med. Chem.</i>	18	2402-2411	2010
Salim MTA, <u>Okamoto M</u> , Hosoda S, Aoyama H, Hashimoto Y, <u>Baba M</u>	Anti-bovine viral diarrhea virus activity of novel diphenylmethane derivatives	<i>Antiviral Chem. Chemother</i>	20	193-200	2010
Misawa T, Salim MTA, <u>Okamoto M</u> , <u>Baba M</u> , Aoyama H, Hashimoto Y, Sugita K	Synthesis and anti-hepatitis C virus activity of morpholino triazine derivatives	<i>Heterocycles</i>	81	1419-1426	2010
Aoyama H, <u>Baba M</u> , Hashimoto Y	Nitrogen-Containing Fused-Heteroaromatic Compounds as Anti-Bovine Viral Diarrhea Virus (BVDV) Agents	<i>Curr. Bioact. Compd</i>	6	118-128	2010
Salim MTA, Goto Y, Hamasaki T, <u>Okamoto M</u> , Aoyama H, Hashimoto Y, Musiu S, Paeshuyse J, Neyts J, Froeyen M, Herdewijn P, <u>Baba M</u>	Highly potent and selective inhibition of bovine viral diarrhea virus replication by $\gamma$ -carboline derivatives	<i>Antiviral Res.</i>	88	263-268	2010
Aoyama H, Sugita K, Nakamura M, Aoyama A, Salim MTA, <u>Okamoto M</u> , <u>Baba M</u> , Hashimoto Y.	Fused heterocyclic amino compounds as anti-hepatitis C virus agents	<i>Bioorg. Med. Chem.</i>	In press		
Y. Uchiho, M. Shimojo, <u>K. Kajikawa</u>	Electro-optic effect and optical rectification in gold nanoparticles immobilized above a gold surface	<i>J. Phys. D: Applied Physics</i>	43	495101 (4pages)	2010
T. Yamaguchi, H. Okawa, K. Hashimoto. <u>K. Kajikawa</u>	Formation Process of Self-Assembled Monolayer on Gold Nanosphere Probed by Second Harmonic Generation	<i>Langmuir</i>	26(18)	14543-14547	2010

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
A. Syahir, H. Mihara, <u>K. Kajikawa</u>	A New Optical Label-Free Biosensing Platform Based on a Metal-Insulator-Metal Structure	<i>Langmuir</i>	26(8)	6053-6057	2010
Y. Uchiho, M. Shimojo, K. Furuya, <u>K. Kajikawa</u>	Optical Response of Gold-Nanoparticle-Amplified Surface Plasmon Resonance Spectroscopy	<i>J. Phys. Chem.</i>	114	4816-4824	2010
T. Yamaguchi, H. Okawa, K. Hashimoto, M. Shimojo, <u>K. Kajikawa</u>	Phase of the electric field localized at surface-immobilized gold nanospheres determined by second-harmonic interferometry	<i>Phys. Rev. B.</i>	83(8)	085425 (7pages)	2011
Uto H, Kanmura S, Takami Y, <u>Tsubouchi H</u>	Clinical proteomics for liver disease: a promising approach for discovery of novel biomarkers	<i>Proteome Sci</i>	8	70	2010
Oketani M, <u>Tsubouchi H</u>	Current status and prevention of fulminant hepatitis due to hepatitis B reactivation	<i>Nippon Shokakibyō Gakkai Zasshi</i>	107	1426-1433	2010
Ide T, Sata M, Sakisaka S, Nakamuta M, Fujiyama S, Mizuta T, Tahara K, Fujisaki K, Komorizono Y, Watanabe H, Morita Y, <u>Tsubouchi H</u>	Peginterferon-alpha-2b plus ribavirin therapy in patients with chronic hepatitis C as assessed by a multi-institutional questionnaire in Japan	<i>Hepato Res</i>	40	557-565	2010
Kanmura S, Uto H, Sato Y, Kumagai K, Sasaki F, Moriuchi A, Oketani M, Ido A, Nagata K, Hayashi K, Stuver SO, <u>Tsubouchi H</u>	The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma	<i>J Gastroenterol</i>	45	459-467	2010
Nishida C, Uto H, Oketani M, Tokunaga K, Nosaki T, Fukumoto M, Oku M, Sogabe A, Moriuchi A, Ido A, <u>Tsubouchi H</u>	Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C	<i>J Gastroenterol</i>	45	326-334	2010
Oketani M, Ido A, <u>Tsubouchi H</u>	Changing etiologies and outcomes of acute liver failure: A perspective from Japan	<i>Gastroenterol Hepatol</i>	Suppl 1	65-71	2011

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Koichi Tokuda, <u>Junichiro Nishi</u> , Naoko Imuta, Rika Fujiyama, Akira Kamenosono, Kunihiro Manago and Yoshifumi Kawano	Characterization of typical and atypical enteroaggregative <i>Escherichia coli</i> in Kagoshima, Japan: biofilm formation and acid resistance	<i>Microbiol Immunol</i>	54	320-329	2010
Kentaro Ueno, <u>Junichiro Nishi</u> , Naoko Imuta, Koichi Tokuda and Yoshifumi Kawano	Presence of multiple copies of capsulation loci in invasive <i>Haemophilus influenzae</i> type b (Hib) strains in Japan before introduction of the Hib conjugate vaccine	<i>Microbiol Immunol</i>	54	160-163	2010



#### IV. 研 究 成 果 の 刊 行 物 ・ 別 刷

## Multiple Mechanisms for Exogenous Heparin Modulation of Vascular Endothelial Growth Factor Activity

Errol Wijelath,<sup>1\*</sup> Mayumi Namekata,<sup>1</sup> Jacqueline Murray,<sup>1</sup> Mai Furuyashiki,<sup>2</sup> Siyuan Zhang,<sup>3</sup> Daniel Coan,<sup>1</sup> Masahiro Wakao,<sup>4</sup> Robert B. Harris,<sup>5</sup> Yasuo Suda,<sup>2,4</sup> Lianchun Wang,<sup>3</sup> and Michael Sobel<sup>1</sup>

<sup>1</sup>Department of Surgery, Division of Vascular Surgery, VA Puget Sound Health Care System and the University of Washington School of Medicine, Seattle, Washington

<sup>2</sup>SUDx-Biotec Corporation, Kobe, Japan

<sup>3</sup>Department of Biochemistry and Molecular Biology, Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia

<sup>4</sup>Department of Nanostructure and Advanced Materials, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan

<sup>5</sup>Commonwealth Biotechnologies, Inc., Richmond, Virginia

### ABSTRACT

Heparin and heparin-like molecules are known to modulate the cellular responses to vascular endothelial growth factor-A (VEGF-A). In this study, we investigated the likely mechanisms for heparin's influence on the biological activity of VEGF-A. Previous studies have shown that exogenous heparin's effects on the biological activity of VEGF-A are many and varied, in part due to the endogenous cell-surface heparan sulfates. To circumvent this problem, we used mutant endothelial cells lacking cell-surface heparan sulfates. We showed that VEGF-induced cellular responses are dependent in part on the presence of the heparan sulfates, and that exogenous heparin significantly augments VEGF's cellular effects especially when endogenous heparan sulfates are absent. Exogenous heparin was also found to play a cross-bridging role between VEGF-A<sub>165</sub> and putative heparin-binding sites within its cognate receptor, VEGFR2 when they were examined in isolation. The cross-bridging appears to be more dependent on molecular weight than on a specific heparin structure. This was confirmed by surface plasmon resonance binding studies using sugar chips immobilized with defined oligosaccharide structures, which showed that VEGF-A<sub>165</sub> binds to a relatively broad range of sulfated glycosaminoglycan structures. Finally, studies of the far-UV circular dichroism spectra of VEGF-A<sub>165</sub> showed that heparin can also modulate the conformation and secondary structure of the protein. *J. Cell. Biochem.* 111: 461–468, 2010. © 2010 Wiley-Liss, Inc.

**KEY WORDS:** VEGF-A; VEGFR2; HEPARIN; ENDOTHELIAL CELL; Ndst

Vascular endothelial growth factor-A (VEGF-A), a secreted glycoprotein, plays a key role in regulating both normal and pathological angiogenic processes [Dvorak, 2005]. The importance of VEGF-A in vascular development was demonstrated in mouse models showing that loss of even a single VEGF-A allele results in lethal vascular defects [Carmeliet et al., 1996]. The main function of VEGF-A is to promote endothelial cell proliferation, migration and survival [Ferrara et al., 2003]. The most abundant spliced variant form of VEGF-A is VEGF-A<sub>165</sub>, which contains a heparin binding

domain encoded by exons 6 and 7 [Tischer et al., 1991]. Heparins and heparan sulfates are known to have pleiomorphic effects on the biological actions of VEGF-A [Neufeld et al., 1999]. However, the elucidation of heparin's effects and mechanisms of actions are complicated by the multiplicity of potential heparin-binding partners involved. Not only does VEGF-A<sub>165</sub> bind heparin, but so do its principal receptor, VEGFR2, as well as VEGFR1 and neuropilin, a co-receptor for VEGF-A [Dougher et al., 1997; Soker et al., 1998; Park and Lee, 1999]. Furthermore, endothelial cells

Grant sponsor: NIH; Grant numbers: R01HL097182, P41RR005351; Grant sponsor: Japan Science and Technology Agency.

\*Correspondence to: Dr. Errol Wijelath, PhD, Department of Surgery, Division of Vascular Surgery, VA Puget Sound Health Care System, S151, 1660, S Columbian Way, Seattle, WA 98108. E-mail: errolw@u.washington.edu

Received 12 February 2010; Accepted 28 May 2010 • DOI 10.1002/jcb.22727 • © 2010 Wiley-Liss, Inc.

Published online 3 June 2010 in Wiley Online Library (wileyonlinelibrary.com).



present other heparin-binding sites on their cell surface, including the heparan sulfate proteoglycans (HSPG) [Neufeld et al., 1999]. Exogenous heparin potentiates the binding of VEGF-A to endothelial cells and promotes endothelial cell proliferation, migration and tube formation [Gitay-Goren et al., 1992; Ono et al., 1999; Ashikari-Hada et al., 2005; Lake et al., 2006]. However, most studies of this phenomenon have employed chlorate or heparinase treatments of endothelial cells, which may have unforeseen effects on cellular responses. This present study was undertaken to elucidate the range of influences of heparin on VEGF-A activity, beginning with an endothelial cell line that constitutively lacks sulfation of the cell-surface heparan sulfates, continuing with studies of heparin modulation of VEGF-receptor binding in cell-free systems, and concluding with an examination of the influence of glycosaminoglycan structure on VEGF-A binding and protein conformation.

## MATERIALS AND METHODS

### VEGF PROTEIN

VEGF-A<sub>165</sub> was a gift from Genetech. VEGF-A<sub>121</sub> was expressed in *Pichia pastoris* as described by the manufacturer (Invitrogen).

### HEPARINS

Throughout our experiments we employed a standard unfractionated porcine mucosal heparin (molecular weight ~15,000 Da) that has been thoroughly characterized (Celsus, Inc.). For SPR experiments, low molecular weight heparins (LMWH) were prepared by periodate/alkali treatment of a comparable porcine heparin (Nacalai Tesque, Kyoto, Japan), and by fractionation according to their molecular weight as we have previously described [Suda et al., 1993]. For circular dichroism, a LMWH ~5,000 Da was purchased from Calbiochem and a high molecular weight heparin of ~21,000 Da was prepared, as previously described, by affinity fractionation of the standard unfractionated heparin, using a heparin-binding peptide [Poletti et al., 1997].

### ENDOTHELIAL CELL LINES

Ndst2<sup>-/-</sup> and its daughter Ndst1<sup>-/-</sup> Ndst2<sup>-/-</sup> mouse lung endothelial cells were generated as previously described [Wang et al., 2005]. In this current study, we utilized these two mutant endothelial cell lines and also a newly generated Ndst1<sup>+/-</sup>Ndst2<sup>+/-</sup> line as wild-type control which was similarly derived from wild-type mice. All three endothelial cell lines were derived from fully backcrossed C57Bl/6J mice and possess the same genetic background.

### FLOW CYTOMETRY ANALYSIS OF GLYCOSAMINOGLYCAN AND GROWTH FACTOR BINDING TO ENDOTHELIAL CELLS LACKING NDST ENZYMES

Endothelial cells (80% confluent) were harvested with 2 mM EDTA containing 0.1% BSA in PBS (PBS-B-E buffer) and incubated with mouse IgM type anti-CS antibody (1:200, Sigma) or anti-heparan sulfate antibody (10E4, 1:500, Seikagaku) respectively for 1 h with shaking at 4°C. Normal mouse IgM staining served as background control. For basic fibroblast growth factor (FGF-2) binding studies,

harvested endothelial cells were incubated with 0.6 µg/ml biotinylated-FGF-2 in PBS-B-E buffer on ice for 30 min. To detect cell surface VEGF binding, endothelial cells were incubated for 1 h at 4°C with recombinant human biotinylated VEGF<sub>165</sub> (1.1 µg/ml in PBS; R&D Systems). As controls, the same cells were incubated with an irrelevant biotinylated protein (soybean trypsin inhibitor) (Invitrogen; 8 µg/ml for 45 min at 4°C). Cells were then washed with PBS-B-E buffer and incubated with FITC-conjugated goat anti-mouse IgM (for anti-HS and anti-CS antibody, 1:1000, Invitrogen) for 1 h or with FITC-streptavidin (1:1,000, Pierce) for 15 min on ice. Thereafter, the cells were washed twice with PBS-B-E buffer and analyzed by Cell Lab Quanta SC flow cytometer (Beckman Coulter). Twenty thousand cell counts were collected and analyzed by the FlowJo software (Tree Star, Inc.).

### MEASUREMENT OF ERK AND VEGFR2 PHOSPHORYLATION

Preliminary experiments established that 5 ng/ml was the concentration for VEGF-A that activated Erk and VEGFR2 that was below the saturation point. This concentration of VEGF-A allowed us to analyze the change in the phosphorylation state of Erk and VEGFR2 in the presence of heparin. Detection and analysis of Erk and VEGFR2 phosphorylation were performed as described previously [Wijelath et al., 2006]. Signal densities from Western blots were quantified using the NIH Image program, and the results of three or more independent experiments pooled for analysis. Activated Erk and VEGFR2 were expressed as fold increase in phosphorylation over basal (unstimulated) levels.

### SURFACE PLASMON RESONANCE BINDING STUDIES

Surface plasmon resonance (SPR) experiments were performed with an SPR-670M (Mortech, Yokohama, Japan) under the manufacturer's recommended guidelines with slight modifications [Wakao et al., 2008]. Two different approaches were taken. First, heparin modulation of VEGF-165 binding to its receptor VEGFR2 was measured. VEGFR2-Fc protein was immobilized on protein A-coated gold sensor chips. The carboxyl groups immobilized chips were purchased from SUDx-Biotec (Kagoshima, Japan) and were activated for 15 min with a mixture of 0.2 M 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and 0.05 M *N*-hydroxysuccinimide in 90% dioxane. With continuous monitoring of resonance units, Protein A was immobilized to the activated chip by injecting 2 × 100 µl (100 µg/ml) in PBS pH 6. Excess reactive groups were quenched with 1 M ethanolamine-HCl, pH 8.5. VEGFR2-Fc (10 µg/ml) was then immobilized to protein A by injecting 2 × 100 µl in PBS. A flow cell without immobilized VEGFR2-Fc served as the negative control. For binding studies, VEGF-A was injected into the flow cells in PBS containing 0.05% Tween-20 (PBST) with or without heparin. VEGF-A/heparin mixtures were pre-incubated for 10 min at room-temperature before injection into the flow cell. Sensor chips were regenerated by treating with 1.5 M glycine/NaOH, 3 M NaCl, pH 9.

For the second approach, a novel "sugar chip" technology was used to measure the affinity of VEGF-A for a library of different, defined oligosaccharide structures. The array type sugar chips (GAG-chips) were supplied from SUDx-Biotec as previously described [Suda et al., 2006]. Totally synthetic, defined disaccharide

structures derived from heparin and related glycosaminoglycans, as well as positive and negative controls (12 in all) were immobilized on the chips of SPR imaging apparatus (SPRinter, Toyobo, Osaka, Japan). The solvent for the binding experiments was PBST at pH 7.4, run at a flow rate of 15  $\mu\text{l}/\text{min}$  at 25°C containing a range of concentrations of VEGF-A (12–400 nM) and heparin. Binding was recorded as resonance units, and the kinetic binding parameters deconvoluted using the manufacturer's software to calculate on- and off-rates and dissociation constants.

#### CIRCULAR DICHROISM

The far-UV circular dichroism spectra of VEGF-A<sub>165</sub> and VEGF-A<sub>121</sub> protein were measured in a Jasco Model 715 Spectropolarimeter equipped with a Jasco Model PTC-348WI Peltier temperature controller. The system is operated by Jasco Hardware Manager (ver. 1.50.00) and data collected by Jasco J-700 Analysis Software (ver. 1.50.01). Protein samples were assayed at 2.78  $\mu\text{M}$  (0.1 mg/ml) VEGF-A. A measured volume of 200  $\mu\text{l}$  of protein was placed in a cell with a 0.1 cm light path length, thermostatted at 20°C. The samples were scanned from 350 to 170 nm at a scan speed of 100 nm/min, and two spectra were accumulated for each sample. Circular dichroism spectra were measured for the protein alone, and after the sequential addition of 0.5  $\mu\text{M}$  increments of unfractionated heparin. Spectral data were analyzed for secondary structure using Dicroprot (ver 2.4).

## RESULTS

#### HEPARAN SULFATION IS MARKEDLY REDUCED IN NDST1/2-NULL CELLS

To clarify the role of HSPG, particularly their sulfated moieties, we studied the effects of heparins and VEGF-A on mutant strains of mouse endothelial cells that naturally lacked sulfated heparans. We first analyzed the degree of sulfation on Ndst1<sup>+/+</sup>Ndst2<sup>+/+</sup> (wild-type), Ndst1<sup>+/+</sup>Ndst2<sup>-/-</sup>, and Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup> endothelial cell lines using an anti-heparan sulfate antibody 10E4. Ablation of both Ndst1 and Ndst2 attenuates cell surface 10E4 binding by more than 80% whereas Ndst2 ablation does not alter endothelial cell surface heparan sulfate structure, when compared to Ndst1<sup>+/+</sup>Ndst2<sup>+/+</sup> mouse endothelial cells (Fig. 1A). The residual 20% binding of Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup> cells may reflect the binding of the antibody to the *N*-acetylated glucosamine structure of heparan sulfate since the 10E4 antibody recognizes both *N*-sulfated and *N*-acetylated structures of heparan sulfate. To confirm the reduced sulfation of the Ndst1/2<sup>-/-</sup> endothelial cell surface heparan sulfate, we analyzed the binding of FGF-2 since FGF-2 binding to cell surface heparan sulfate is critically dependent on *N*- and 2-*O*-sulfation. Simultaneous ablation of Ndst1 and Ndst2 attenuated cell surface FGF-2 binding by more than 90% (Fig. 1B). However, Ndst2 ablation alone did not alter endothelial cell surface FGF-2 binding. To determine whether the Ndst1/2 ablation alters cell surface chondroitin sulfates (CS) expression, the mutant cells were stained with anti-CS antibody. Cell surface CS levels were similar among Ndst1<sup>+/+</sup>Ndst2<sup>+/+</sup>, Ndst1<sup>+/+</sup>Ndst2<sup>-/-</sup> and Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup> endothelial cells, demonstrating that Ndst ablation did not affect CS expression (Fig. 1C). We next examined the binding of VEGF-A on these cell-

lines. Cell surface VEGF-A binding analysis showed that, although Ndst2 ablation does not alter endothelial cell surface VEGF-A binding, the simultaneous ablation of Ndst1 and Ndst2 attenuated cell surface VEGF-A binding by about 85% (Fig. 1D). The residual 15% cell surface VEGF-A binding may reflect low affinity binding to VEGFR2. Taken together, these cell surface profiles illustrate that the Ndst1<sup>+/+</sup>Ndst2<sup>-/-</sup> endothelial heparan sulfate possesses normal heparan sulfate structure, whereas the Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup> endothelial heparan sulfates have very low or no sulfates. CS expression was unaffected in all cell lines.

#### ACTIVATION OF ERK AND VEGFR2

As shown above, the Ndst1<sup>+/+</sup>Ndst2<sup>-/-</sup> and the Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup> endothelial cell lines are suitable cell-systems to examine the requirement of endogenous heparan sulfates and also the role of exogenous heparin for VEGF-A signaling. Ndst1<sup>+/+</sup>Ndst2<sup>+/+</sup>, Ndst1<sup>+/+</sup>Ndst2<sup>-/-</sup> and Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup> mouse endothelial cell cultures were simultaneously exposed to VEGF-A (5 ng/ml) and different concentrations of unfractionated heparin (1–50  $\mu\text{g}/\text{ml}$ ). Erk phosphorylation was measured after 5 min. Figure 2 illustrates the results of three independent experiments. VEGF alone modestly increased Erk phosphorylation in all three cell lines. Increasing concentrations of exogenous heparin steadily increased Erk phosphorylation induced by VEGF-A (Fig. 2A). However, cells lacking endogenous heparan sulfates (Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup>) responded much more dramatically to exogenous heparin, far exceeding the increase in Erk induced by heparin/VEGF-A in the Ndst1<sup>+/+</sup>Ndst2<sup>+/+</sup> and Ndst1<sup>+/+</sup>Ndst2<sup>-/-</sup> cells at 10  $\mu\text{g}/\text{ml}$  of heparin only ( $P < 0.01$ , *t*-test). We then investigated how exogenous heparin would influence VEGF's interaction with its principle cognate receptor, VEGFR2. Figure 2B shows that the pattern of VEGFR2 responses to heparin/VEGF was quite similar to the Erk responses. The Ndst1<sup>-/-</sup>Ndst2<sup>-/-</sup> cells deficient in sulfated heparans induced more VEGFR2 phosphorylation in response to heparin (10  $\mu\text{g}/\text{ml}$ ) than did the Ndst1<sup>+/+</sup>Ndst2<sup>+/+</sup> and Ndst1<sup>+/+</sup>Ndst2<sup>-/-</sup> cells ( $P < 0.05$ , *t*-test). Heparin alone had no effect on Erk or VEGFR2 phosphorylation (data not shown).

#### HEPARIN MODULATION OF VEGF-VEGFR2 RECEPTOR BINDING

Because both VEGF-A<sub>165</sub> and VEGFR2 bind heparin [Gitay-Goren et al., 1992; Dougher et al., 1997], an additional mechanism for heparin enhancement of VEGF activity is the cross-bridging or stabilization of the VEGF-VEGFR2 complex by heparin. Surface plasmon resonance (SPR) techniques were used to measure VEGF-A binding to VEGFR2 in a cell-free system in real-time. Unfractionated heparin promoted VEGF-A binding to VEGFR2, with maximal binding observed at 1  $\mu\text{g}/\text{ml}$  heparin (Fig. 3A). At higher concentrations of heparin (100  $\mu\text{g}/\text{ml}$ ), binding was inhibited. Low molecular weight heparins ( $\leq 5,000$  Da) did not enhance VEGF-A binding (Fig. 3B).

#### STRUCTURAL SPECIFICITY OF HEPARIN-VEGF BINDING BY SPR

To investigate the structural specificity of heparin binding to VEGF-A, we immobilized a library of heparin and other sulfated glycosaminoglycan partial structures onto "array type sugar






Fig. 1. Analysis of cell surface glycosaminoglycan sulfation in mouse endothelial cells lacking the *Ndst* enzymes. Flow cytometry was employed to phenotype the surface expression of sulfated heparans in mouse endothelial cells of these genotypes: *Ndst1*<sup>+/-</sup>*Ndst2*<sup>+/-</sup> (wild-type), *Ndst1*<sup>+/-</sup>*Ndst2*<sup>-/-</sup> and *Ndst1*<sup>-/-</sup>*Ndst2*<sup>-/-</sup>. Cells were exposed to the primary antibody or biotinylated ligand, and then stained with a secondary FITC-conjugated goat anti-mouse IgM or with FITC-streptavidin. In each panel, the gray histograms represent controls (either irrelevant primary isotype antibody, or only the secondary antibody), and the red histograms are cells stained with the antibody of interest. Panel A: Anti-heparan sulfates antibody that is sulfation specific; (B) biotinylated FGF-2; (C) anti-chondroitin sulfates (anti-CS) antibody; (D) biotinylated VEGF-A<sub>165</sub>. Data are representative of three separate experiments.

chips" and measured their kinetic binding of VEGF-165. Table I summarizes these findings. Among the heparin partial structures, those containing glucosamine *N*-sulfates 6-*O*-sulfates (GlcNS6S) had lower  $K_D$ , independent of the presence or absence of 2-*O*-sulfation at the iduronic/glucuronic acid residue. For the chondroitin sulfates partial structures, 6-*O*-sulfation of the *N*-acetylgalactosamine (GalNAc) moiety conferred a lower  $K_D$  than did 4-*O*-sulfation.

#### HEPARIN MODULATION OF VEGF SECONDARY STRUCTURE

Circular dichroism spectra were measured from VEGF-A<sub>165</sub> alone, and after the sequential addition of increments of unfractionated heparin. Control spectra were obtained from heparin alone, as well as heparin with VEGF-A<sub>121</sub>, which does not bind heparin. Sequential additions of heparin reached a maximal effect at 0.5  $\mu$ M heparin, and no additional conformational change was observed at higher concentrations. Figure 4 shows that the negative peak of VEGF-A<sub>165</sub>




Fig. 2. VEGF-mediated Erk and VEGFR2 phosphorylation in mouse endothelial cells lacking heparan sulfates. Mouse endothelial cell-lines lacking heparan sulfates ( $Ndst1^{-/-}Ndst2^{-/-}$ ) and normally sulfated mouse endothelial cell-lines ( $Ndst1^{+/+}Ndst2^{+/+}$  and  $Ndst1^{+/+}Ndst2^{-/-}$ ) were incubated in serum-free MCD8 131 medium for 2 h prior to stimulation with VEGF-A for 5 min. Control cultures (Ctrl) received no VEGF-A or heparin treatment. Remaining cultures were stimulated with VEGF-A (5 ng/ml) with or without heparin at the indicated concentrations. V + Hep 1, V + Hep 10 and V + Hep 50 denotes VEGF-A (5 ng/ml), plus heparin 1  $\mu$ g/ml, 10  $\mu$ g/ml and 50  $\mu$ g/ml respectively. A: Phosphorylated Erk and (B) VEGFR2 levels were measured by Western blotting and quantified as described in the Materials and Methods Section. Values are means  $\pm$  SEM (n = 3). Statistical significance was determined by the Wilcoxon rank-sum test. In each panel, the  $Ndst1^{-/-}Ndst2^{-/-}$  was significantly higher than its indicated comparators.

shifted from a minimum at 200.6–209.0 nm. Addition of heparin to VEGF-A<sub>121</sub> showed no change; the spectra were virtually identical in the absence of heparin and at all concentrations of added heparin (data not shown). The CD spectra of VEGF-A<sub>165</sub> were also measured in response to a low molecular weight (~5,000) and high molecular weight heparin (~21,000), and the relative changes in secondary structure were compared to the standard unfractionated heparin (~15,000) using an average of the algorithms of Chen, Bolotina, and Chang (Table II). Spectral shifts were essentially complete at a molar ratio of heparin/VEGF-A of 0.54 for the low molecular weight heparin, and 0.36 for the unfractionated and high molecular weight heparins. The secondary structure of VEGF-A alone was predominantly random coil and  $\beta$ -sheet, with lesser elements of  $\beta$ -turn and  $\alpha$ -helix respectively. Table II shows that upon the addition of saturating concentrations of heparins, the proportion of  $\alpha$ -helix increased significantly in proportion to the molecular weight of the heparin.

## DISCUSSION

The biosynthesis of heparan sulfate is a complex process, involving more than 26 enzymes. In particular, Ndst catalyzes the deacetylation and *N*-sulfation of the *N*-acetylglucosamine residues in heparan sulfates and plays an essential role in generation of ligand binding sites in mature heparan sulfates. Four related *Ndst* genes are identified (*Ndst1*–4). However in mouse lung endothelial cells only *Ndst1* and *Ndst2* are abundantly expressed. In our previous studies, we derived  $Ndst2^{-/-}$  and its daughter  $Ndst1^{-/-}Ndst2^{-/-}$  mouse lung endothelial cells [Wang et al., 2005]. In this current study, we employed these endothelial cell lines to further define how heparins modulate VEGF-A biological effects. Cells lacking the *Ndst2* enzyme ( $Ndst1^{+/+}Ndst2^{-/-}$ ) still express normal levels of sulfated heparans, and in these experiments they showed a typical response to heparin: enhancement of VEGF-A effects at low concentrations. However, in

cells lacking both *Ndst* enzymes ( $Ndst1^{-/-}Ndst2^{-/-}$ ) which are devoid of sulfated heparans, exogenous heparin dramatically enhanced VEGF response to VEGFR2 and Erk phosphorylation. One hypothesis is that under normal conditions, heparan sulfate proteoglycans (HSPGs) modulate VEGF-A biological responses in both directions—that is, enhance VEGF signaling but also moderate it. On the positive side, the cell-surface HSPGs are binding sites for VEGF-A, enhancing and stabilizing its binding to its cognate tyrosine receptor kinases. In the absence of sulfated heparans, VEGF-cell interactions would be less effective (as observed especially for VEGFR2, the immediate cellular responder), and exogenous heparin would enhance VEGF-cell binding through cross-bridging effects. On the inhibitory side, engagement of VEGF-A with HSPGs could produce counter-regulatory effects, independently modulating the conventional pathways to VEGF-A activation of the cell. Thus, cells lacking sulfated HSPGs would show even greater enhancement of VEGF-A by exogenous heparin, because they lack the intrinsic counter-regulation initiated by independent HSPG signaling. We recognize that this is a speculative theory, which will require more extensive, focused experiments to confirm or deny it. However, one abundant family of HSPGs, the syndecans, are known to signal independently through their cytoplasmic domains [Oh et al., 1997], and other studies have shown that HSPG can inhibit transforming growth factor beta and platelet derived growth factor signaling [Koyama et al., 1998; Chen et al., 2006].

This research also examined cell-independent mechanisms for heparin's effects. We found in cell-free systems that heparin enhanced the binding of VEGF-A to VEGFR2. However, the concentration of heparin (1  $\mu$ g/ml) required for maximal VEGF-A binding to VEGFR2 was 10-fold less when compared to the concentration of heparin (10  $\mu$ g/ml) required for optimal VEGF-A induced Erk activation and VEGFR2 phosphorylation. One plausible explanation for the discrepancy in the optimal concentrations of heparin required in the two assays is that the binding assays were




Fig. 3. Heparin modulation of VEGF-A binding to VEGFR2. SPR technology was employed to measure VEGF-A binding to immobilized VEGFR2, as described in the Materials and Methods Section. A: Various concentrations of unfractionated heparin (average molecular weight ~15 kDa) mixed with VEGF-A (5 ng/ml) were injected over immobilized VEGFR2-Fc chimera at a flow rate of 15  $\mu$ l/min. B: Different molecular weight heparins (1  $\mu$ g/ml) mixed with VEGF-A (5 ng/ml) were injected over immobilized chimeric VEGFR2-Fc protein at a flow rate of 15  $\mu$ l/min. Data are presented as means  $\pm$  SEM ( $n = 3$ ).




Fig. 4. Circular dichroism spectra of VEGF-A<sub>165</sub>. Spectral scans were obtained as described in the Materials and Methods Section. Upon the addition of increments of heparin, there was a maximal shift in the negative peak of VEGF from 200.6 to 209 nm, at a heparin concentration of 0.5  $\mu$ M. Heparin alone showed no shift in the area of interest.

carried out in a cell-free system so that heparin can bind to only VEGF or VEGFR2. However, the Erk and VEGFR2 phosphorylation assays were carried out in endothelial cell lines. In this system, heparin can bind not only to VEGF-A and VEGFR2 but to other ligands that are on the endothelial cell surface and thus a higher concentration of heparin was needed for promoting optimal VEGF-A responses.

Considering that both the VEGF-A and VEGFR2 bind heparin [Dougher et al., 1997], these data suggest that exogenous heparin may also play a cross-bridging role in supporting and sustaining the engagement of the protein ligand with its receptor. This behavior mirrors the effects of heparin on another growth factor/receptor complex, FGF, in which heparin forms a ternary complex with the ligand and receptor [Pellegrini et al., 2000]. In both cases, receptor dimerization contributes to signaling [Li et al., 2008], although unlike FGF, VEGF already exists as a natural dimer. Thus, the current binding studies strongly suggest that the biophysical actions of heparins in FGF-receptor interactions may also apply to VEGF-receptor interactions.

TABLE I. Structural Specificity of VEGF Binding to Defined Glycosaminoglycan Structures

Sugar sequence	Partial structure of	$K_D$ (nM)	$k_a \times 10^3$ ( $M^{-1} sec^{-1}$ )	$k_d \times 10^{-3}$ ( $sec^{-1}$ )
GlcA $\beta$ 1-3GalNAc4S $\beta$ 1-6Glc	Chondroitin sulfates A	34.1	115.6	3.94
GlcA $\beta$ 1-3GalNAc6S $\beta$ 1-6Glc	Chondroitin sulfates C	14.7	111.0	1.64
GlcA2S $\beta$ 1-3GalNAc6S $\beta$ 1-6Glc	Chondroitin sulfates D	12.6	88.7	1.12
GlcA $\beta$ 1-3GalNAc4S6S $\beta$ 1-6Glc	Chondroitin sulfates E	19.6	64.6	1.26
GlcNS $\alpha$ 1-4GlcA $\beta$ 1-6Glc	Heparin	66.1	62.7	4.15
GlcNS $\alpha$ 1-4IdoA2S $\alpha$ 1-6Glc	Heparin	46.8	68.4	3.20
GlcNS6S $\alpha$ 1-4GlcA $\beta$ 1-6Glc	Heparin	12.0	88.0	1.05
GlcNS6S $\alpha$ 1-4IdoA2S $\alpha$ 1-6Glc	Heparin	16.5	78.5	1.30
GlcA $\beta$ 1-6Glc	Control	151.9	73.9	11.23
Gal $\beta$ 1-4Glc	Control	NB	NB	NB
Glc $\beta$ 1-6Glc	Control	NB	NB	NB
Unfractionated heparin	Heparin	11.3	49.1	0.56

Surface Plasmon Resonance studies were performed as described in the Materials and Methods Section, using a multi-channel analyzer and a sugar-chip array immobilized with the defined synthetic structures indicated. Dissociation constant ( $K_D$ ), on-rate ( $k_a$ ), and off-rate ( $k_d$ ) were calculated from multiple runs, using the manufacturer's software. NB, no binding.

TABLE II. Changes in the Estimated Percentages of Secondary Structure of VEGF in Response to Heparins

	$\alpha$ -Helix	$\beta$ -Sheet	$\beta$ -Turn	Random coil	Total
VEGF alone	5	32	20	43	100
LMWH	9	25	22	44	100
Unfx heparin	15	22	22	41	100
DM spectra	33	1	24	42	100

CD spectra were obtained in the absence and presence of saturating concentrations of heparin (0.9 mol/mol LMWH/VEGF, 0.35 mol/mol for unfractionated (unfx) and high molecular weight heparin (HMWH)). The percentage of secondary structure was estimated using the average of 3 algorithms, calculated from two independent spectral scans each.

An additional, cell-independent effect of heparin was documented by circular dichroism studies. Heparin binding to VEGF-A<sub>165</sub> induced a shift in the protein's negative peak from 200.6 to 209 nm. No change was seen with heparin alone, or when heparin was added to VEGF-A<sub>121</sub>. This heparin-induced spectral shift in VEGF-165 corresponded to an increase in the helix content of the protein which was proportional to the molecular weight of the heparin. Heparin is known to modulate the secondary structure of a number of heparin-binding proteins, including the classic case of antithrombin III [Stone et al., 1982; Tyler-Cross et al., 1996] and FGF [Prestrelski et al., 1992]. In previous work with antithrombin III, we have shown that heparin specifically increases the helical content of that protein [Ferran et al., 1992]. There are also precedents from other proteins to suggest that shifts in helix content induced by heparin may affect the biological function of the protein [Almeida et al., 1999]. However, further functional studies will be needed to confirm this for VEGF. We have used the terms heparin and heparan both of which share the same core disaccharide structure, but differ in the density and distribution of sulfated regions. Heparans are less sulfated overall, but in their areas of higher sulfation they resemble heparin in its type and density of sulfation [Robinson et al., 2006].

The effects of a 2-*O*-sulfation in the uronic acid moiety (glucuronic or iduronic) on VEGF-A binding are very modest, if noticeable at all. For an *N*- and 6-*O*-sulfated structure, the presence or absence of a 2-*O* sulfate makes very little difference  $K_D$  (12 vs. 16.5). Likewise, starting with a single *N*-sulfated structure, the addition of a 2-*O* sulfate has only a modest effect on the  $K_D$  (66 vs. 47), compared with the dramatic effect of adding a 6-*O* sulfate (66 vs. 12). A similar tendency was shown in the case of the partial structures of chondroitin sulfates. The 2-*O*-sulfation of the glucuronic acid did not affect the  $K_D$  (13 vs. 15 or 20), but the 6-*O*-sulfation more dramatically affected the  $K_D$  (34 vs. 15). This suggests that the interaction depends on the 6-*O*-sulfated structure more than that of the net charge, or the 2-*O* sulfation. These findings are indeed in keeping with the research of Robinson et al. [2006] and Ono et al. [1999]. Looking across different glycosaminoglycan families there are similarities and differences between the structural determinants. For dermatan and heparan, 6-*O* sulfation of the hexosamine residue appears to be important for binding HGF and VEGF, while 2-*O* sulfation of iduronic residues is not essential [Lyon et al., 1994, 1998]. Lyon et al. has found that for dermatan sulfates, the iduronic residue appears to be quite important, yet not so critical for heparins/heparans. Holmborn et al. [2004] observed that heparan sulfate synthesized by the Ndst1 and Ndst2 double mutant mouse

embryonic stem cells is still 6-*O*-sulfated but contains no *N*- and 2-*O*-sulfate groups. Our recent studies observed both Ndst1 and Ndst2 are abundantly expressed in endothelial cells [Wang et al., 2005]. Chemical analysis of heparan sulfate synthesized by the Ndst1 and Ndst2 double mutant endothelial cells showed a similar heparan sulfate structural change as reported for the Ndst1 and Ndst2 double mutant mouse embryonic stem cells. The endothelial heparan sulfate structure alteration caused by the Ndst1 and Ndst2 ablation inhibited FGF-2 and VEGF-A binding, which are known to depend on *N*- and/or 2-*O*-sulfation.

We believe that the sulfation pattern of the glycosaminoglycan may be only one of the important determinants for modulation of the complex processes of VEGF-mediated cellular responses. In fact polymer size, as well as the configuration of sulfated domains may be as important for the pro-angiogenic activities of a heparin as are the unique disaccharide structure and specific sulfation. Robinson et al. [2006] has suggested that a heparan sulfate polysaccharide containing a pair of highly sulfated heparin-like regions separated by an unsulfated region functions as a binary ligand that can form a more stable VEGF-heparin complex. Throughout our studies, heparins of larger polymer chain length were more effective in inducing Erk phosphorylation, in promoting VEGF-VEGFR2 binding, and in inducing a conformational change in the VEGF protein. The molecular weight dependency of these processes was also borne out by the work of Rouet et al. [2005], who developed a high molecular weight heparin-mimetic polymer that further promoted VEGF activity. Studies by Mamluk et al. [2002] show that heparin can bind neurophilin and increase the affinity of that heparin-VEGF interaction. Therefore polymer size as well as the site-specificity of sulfations may play a role in promoting the binding of VEGF with both VEGFR2 and neurophilin to form a ternary complex with strong signaling capability.

In conclusion, these data show that exogenous heparin enhances VEGF-induced cellular responses much more significantly in cells lacking sulfated HSPGs, compared with cells that are sulfated. A plausible explanation is that while both cell types benefit from the pro-angiogenic stimuli of preformed VEGF-heparin complexes, the unsulfated cells may be free of the negative feedback induced by growth factor binding to signaling HSPGs like syndecans. Heparin appears to play important biophysical roles for VEGF-A. Heparin promotes VEGF-A binding to its receptor, and likely forms a ternary VEGF-heparin-VEGFR2 complex. Heparin also alters the conformation of VEGF-A<sub>165</sub> protein. The specificity of heparin's actions lies in part in the pattern of sulfation sites, but also appears to depend on the polymer chain length, as one would expect for a cross-bridging role. Our knowledge of VEGF-heparin interactions is still not as far advanced as it is for the FGF system or other growth factors. We are hopeful that this current work will be helpful in refining glycosaminoglycans that can ultimately be employed as modulators of angiogenesis.

## ACKNOWLEDGMENTS

This research was supported by grants from NIH (RO1HL097182 to M.S. and P41RR005351 to L.W. with James H. Prestegard as the PI) and the Japan Science and Technology Agency to Y.S.



## REFERENCES

- Almeida PC, Nantes IL, Rizzi CC, Judice WA, Chagas JR, Juliano L, Nader HB, Tersariol IL. 1999. Cysteine proteinase activity regulation. A possible role of heparin and heparin-like glycosaminoglycans. *J Biol Chem* 274:30433-30438.
- Ashikari-Hada S, Habuchi H, Kariya Y, Kimata K. 2005. Heparin regulates vascular endothelial growth factor165-dependent mitogenic activity, tube formation, and its receptor phosphorylation of human endothelial cells. Comparison of the effects of heparin and modified heparins. *J Biol Chem* 280:31508-31515.
- Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A. 1996. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. *Nature* 380:435-439.
- Chen CL, Huang SS, Huang JS. 2006. Cellular heparan sulfate negatively modulates transforming growth factor-beta1 (TGF-beta1) responsiveness in epithelial cells. *J Biol Chem* 281:11506-11514.
- Dougher AM, Wasserstrom H, Torley L, Shridaran L, Westdock P, Hileman RE, Fromm JR, Anderberg R, Lyman S, Linhardt RJ, Kaplan J, Terman BI. 1997. Identification of a heparin binding peptide on the extracellular domain of the KDR VEGF receptor. *Growth Factors* 14:257-268.
- Dvorak HF. 2005. Angiogenesis: Update 2005. *J Thromb Haemost* 3:1835-1842.
- Ferran DS, Sobel M, Harris RB. 1992. Design and synthesis of a helix heparin-binding peptide. *Biochemistry* 31:5010-5016.
- Ferrara N, Gerber HP, Lecouter J. 2003. The biology of VEGF and its receptors. *Nat Med* 9:669-676.
- Gitay-Goren H, Soker S, Vlodavsky I, Neufeld G. 1992. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface-associated heparin-like molecules. *J Biol Chem* 267:6093-6098.
- Holmborn K, Ledin J, Smeets E, Eriksson I, Kusche-Gullberg M, Kjellen L. 2004. Heparan sulfate synthesized by mouse embryonic stem cells deficient in NDST1 and NDST2 is 6-O-sulfated but contains no N-sulfate groups. *J Biol Chem* 279:42355-42358.
- Koyama N, Kinsella MG, Wight TN, Hedin U, Clowes AW. 1998. Heparan sulfate proteoglycans mediate a potent inhibitory signal for migration of vascular smooth muscle cells. *Circ Res* 83:305-313.
- Lake AC, Vassy R, Di BM, Lavigne D, Le VC, Perret GY, Letourneur D. 2006. Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. *J Biol Chem* 281:37844-37852.
- Li X, Claesson-Welsh L, Shibuya M. 2008. VEGF receptor signal transduction. *Methods Enzymol* 443:261-284.
- Lyon M, Deakin JA, Mizuno K, Nakamura T, Gallagher JT. 1994. Interaction of hepatocyte growth factor with heparan sulfate. Elucidation of the major heparan sulfate structural determinants. *J Biol Chem* 269:11216-11223.
- Lyon M, Deakin JA, Rahmoune H, Fernig DG, Nakamura T, Gallagher JT. 1998. Hepatocyte growth factor/scatter factor binds with high affinity to dermatan sulfate. *J Biol Chem* 273:271-278.
- Mamluk R, Gechtman Z, Kutcher ME, Gasunas N, Gallagher J, Klagsbrun M. 2002. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. *J Biol Chem* 277:24818-24825.
- Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J* 13:9-22.
- Oh ES, Woods A, Couchman JR. 1997. Syndecan-4 proteoglycan regulates the distribution and activity of protein kinase C. *J Biol Chem* 272:8133-8136.
- Ono K, Hattori H, Takeshita S, Kurita A, Ishihara M. 1999. Structural features in heparin that interact with VEGF 165 and modulates its biological activity. *Glycobiology* 9:705-711.
- Park M, Lee ST. 1999. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. *Biochem Biophys Res Commun* 264:730-734.
- Pellegrini L, Burke DF, von DF Mulloy B, Blundell TL. 2000. Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. *Nature* 407:1029-1034.
- Poeltli LF, Bird KE, Marques D, Harris RB, Suda Y, Sobel M. 1997. Structural aspects of heparin responsible for interactions with von Willebrand factor. *Arterioscler Thromb Vasc Biol* 17:925-931.
- Prestrelski SJ, Fox GM, Arakawa T. 1992. Binding of heparin to basic fibroblast growth factor induces a conformational change. *Arch Biochem Biophys* 293:314-319.
- Robinson CJ, Mulloy B, Gallagher JT, Stringer SE. 2006. VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. *J Biol Chem* 281:1731-1740.
- Rouet Y, Hamma-Kourbali Y, Petit E, Panagopoulou P, Katsoris P, Barratout D, Caruelle JP, Courty J. 2005. A synthetic glycosaminoglycan mimetic binds vascular endothelial growth factor and modulates angiogenesis. *J Biol Chem* 280:32792-32800.
- Soker S, Takashima S, Miao HQ, Neufeld G, Klagsbrun M. 1998. Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. *Cell* 92:735-745.
- Stone AL, Beeler D, Oosta G, Rosenberg RD. 1982. Circular dichroism spectroscopy of heparin-antithrombin interactions. *Proc Natl Acad Sci USA* 79:7190-7194.
- Suda Y, Marques D, Kermodé JC, Kusumoto S, Sobel M. 1993. Structural characterization of heparins binding domain for human platelets. *Thromb Res* 69:501-508.
- Suda Y, Arano A, Fukui Y, Koshida S, Wakao M, Nishimura T, Kusumoto S, Sobel M. 2006. Immobilization and clustering of structurally defined oligosaccharides for sugar chips: An improved method for surface plasmon resonance analysis of protein-carbohydrate interactions. *Bioconjug Chem* 17:1125-1135.
- Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, Fiddes JC, Abraham JA. 1991. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. *J Biol Chem* 266:11947-11954.
- Tyler-Cross R, Sobel M, McAdory LE, Harris RB. 1996. Structure-function relations of antithrombin III-heparin interactions as assessed by biophysical and biological assays and molecular modeling of peptide pentasaccharide docked complexes. *Arch Biochem Biophys* 334:206-213.
- Wakao M, Saito A, Ohishi K, Kishimoto Y, Nishimura T, Sobel M, Suda Y. 2008. Sugar chips immobilized with synthetic sulfated disaccharides of heparin/heparan sulfate partial structure. *Bioorg Med Chem Lett* 18:2499-2504.
- Wang L, Fuster M, Sriramarao P, Esko JD. 2005. Endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses. *Nat Immunol* 6:902-910.
- Wijelath ES, Rahman S, Namekata M, Murray J, Nishimura T, Mostafavi-Pour Z, Patel Y, Suda Y, Humphries MJ, Sobel M. 2006. Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: Enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. *Circ Res* 99:853-860.

# Carboxymethyl-chitin promotes chondrogenesis by inducing the production of growth factors from immune cells

Hiroyuki Kariya,<sup>1</sup> Yusuke Yoshihara,<sup>2</sup> Yumiko Nakao,<sup>2</sup> Nobuko Sakurai,<sup>2</sup> Masaru Ueno,<sup>2</sup> Masahito Hashimoto,<sup>1</sup> Yasuo Suda<sup>1</sup>

<sup>1</sup>Department of Nanostructure and Advanced Materials, Graduate School of Science and Engineering, Kagoshima University, Kagoshima, Japan

<sup>2</sup>Japan Medical Materials Corporation, Osaka, Japan

Received 7 October 2008; revised 28 November 2009; accepted 14 December 2009

Published online 31 March 2010 in Wiley InterScience (www.interscience.wiley.com). DOI: 10.1002/jbm.a.32771

**Abstract:** Many techniques have been tested for their ability to restore cartilage defects, but several problems still remain in the complete healing of injured cartilage. In our previous study, we found that a carboxymethyl-chitin/ $\beta$ -tricalcium phosphate (CM-chitin/ $\beta$ -TCP) composite induced cartilage regeneration in the osteochondral defects of rabbits *in vivo*. We also found that CM-chitin stimulated peritoneal exudate cells (PEC) in mice and induced several kinds of inflammatory cytokines and transforming growth factor beta-1 (TGF- $\beta$ 1). In this study, we examined whether CM-chitin is responsible for the induction of chondrogenesis via the production of TGF- $\beta$ 1 *in vitro*. The murine pluripotent cell line C3H10T1/2 was maintained as a micromass culture in conditioned medium prepared from PEC stimulated with and without CM-chitin. CM-chitin-conditioned medium induced RNA expression of the chondrogenic-factor Sox9 and the matrix proteins aggrecan, Col2a1, and

Comp. Their expression levels were decreased in the presence of anti-TGF- $\beta$ 1 antibody. The micromass tissues cultured in CM-chitin conditioned medium at day 21 were clearly stained by Toluidine blue or Alcian blue (histological staining) and collagen II antibody (immunohistological staining), showing the expression of acidic glycosaminoglycan and type II collagen. Similar results were observed in micromass tissue stimulated with TGF- $\beta$ 1 as a positive control. However, no chondrogenesis occurred when CM-chitin was added directly to a C3H10T1/2 cell culture. These results indicated that CM-chitin is a potent inducer of chondrogenesis via the induction of TGF- $\beta$ 1 in immune cells. © 2010 Wiley Periodicals, Inc. *J Biomed Mater Res Part A*: 94A: 1034–1041, 2010.

**Key Words:** CM-chitin, chondrogenesis, TGF- $\beta$ , micromass culture, PEC

## INTRODUCTION

Cartilage is known to have a poor capacity for self-repair because of its low mitotic activity and avascular nature.<sup>1,2</sup> Several medical and surgical methods have been tested for their ability to repair cartilage defects, but complete regeneration of normal cartilage in damaged areas is difficult to achieve due to several problems such as the loosening of artificial joints, degenerative changes in transplanted tissues,<sup>3</sup> and the risk of viral transmission.<sup>4,5</sup>

Recently, tissue-engineering approaches using biocompatible scaffolds have been applied to the treatment of cartilage defects,<sup>6–9</sup> and many materials such as collagen,<sup>10</sup> hydroxyapatite,<sup>11,12</sup> polyglycolic acid,<sup>13</sup> hyaluronic acid,<sup>14,15</sup> and silk<sup>6,7</sup> have been investigated. Such scaffolds play an important role in promoting the formation of cartilage as a temporary extracellular matrix (ECM). In many cases, the scaffold-based tissue-engineering technique requires the addition of growth factors, such as transforming growth factor-beta (TGF- $\beta$ ) or bone morphogenetic protein (BMP). It is well known that these growth factors promote the proliferation or differentiation of chondrocytes from mesenchymal stem cells *in vivo*<sup>16–19</sup> and *in vitro*.<sup>4,7,20,21</sup> Although tissue-engineering techniques that combine scaffolds with

growth factors have great potential for cartilage repair, they are still at an experimental stage because of the cost of using a large amount of expensive recombinant growth factors.

In our previous study, we found that a carboxymethyl-chitin (CM-chitin)/ $\beta$ -tricalcium phosphate ( $\beta$ -TCP) composite induced the regeneration of cartilage in the osteochondral defects of rabbits.<sup>22</sup> The regeneration of cartilage was observed after treatment with the CM-chitin/ $\beta$ -TCP composite but not with  $\beta$ -TCP alone 8 weeks after implantation, indicating that CM-chitin plays a key role in the regeneration of cartilage. Previously, we also showed that CM-chitin stimulated murine peritoneal exudate cells (PEC) to induce the expression of inflammatory cytokines and TGF- $\beta$ 1.<sup>23</sup> TGF- $\beta$ 1 has many functions,<sup>24</sup> including the induction of mesenchymal cell condensation, which is required for *in vitro* chondrogenesis.<sup>25–27</sup> However, no correlation between the stimulation of cells induced with CM-chitin and the regeneration of cartilage has been demonstrated.

The murine pluripotent cell line C3H10T1/2 has been shown to differentiate into myoblasts, osteoblasts, adipocytes, and chondrocytes after treatment with growth factors.<sup>20</sup> C3H10T1/2 cells are attractive for studying

Correspondence to: M. Hashimoto; e-mail: hassy@eng.kagoshima-u.ac.jp

chondrogenesis because they do not spontaneously differentiate under standard culture conditions. Previously, treatment of a high-density micromass culture of C3H10T1/2 cells with TGF- $\beta$ 1 was reported to induce the formation of a three-dimensional (3D) spheroid structure and chondrogenic differentiation.<sup>20,28–30</sup> In this study, we examined the effect of CM-chitin on chondrogenesis using the aforementioned *in vitro* micromass culture system.

## MATERIALS AND METHODS

### CM-chitin preparation and cell stimulation


The CM-chitin (degree of substitution for *O*-carboxymethylation = 79 mol %, degree of deacetylation = 27 mol %) was prepared from chitin extracted from Queen Crab shells, according to a previously reported method.<sup>31</sup> Gel-type CM-chitin was prepared as described<sup>22</sup> and suspended in phosphate-buffered saline (PBS) (10 mg/mL). The level of endotoxin contamination was determined by the Endospecy<sup>®</sup> test (Seikagaku Biobusiness, Tokyo, Japan) according to the manufacturer's instructions.

In this experiment, we used a PEC-utilizing micromass culture as an experimental model of chondrogenesis. Eight to ten-week-old male BALB/cN-sea mice were obtained from Kyudo (Saga, Japan). The animal experiment was performed in accordance with our institutional approval (H18Eng007) and guidelines and the legal requirements of Japan. The mice were injected intraperitoneally (ip) with 0.5 mL of PBS or CM-chitin gel suspension (1 mg/mL). After 24 h stimulation, the ip-administered mice were sacrificed, and 5 mL PBS were injected into the peritoneal cavity. After extracting peritoneal exudate fluid, we collected PEC from the fluid. The number of cells was 1–3  $\times$  10<sup>6</sup> cells per mouse. After 24 h culture in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS, Equitech-Bio, Kerrville, Texas, USA), 100 unit/mL penicillin, and 100  $\mu$ g/mL streptomycin, the supernatants were collected and subjected to ultra-filtration with Amicon Ultra-15 Centrifugal Filter Devices (Millipore, Billerica, MA). The supernatants were concentrated to a 1/45 volume and used as PBS conditioned medium (PBS-sup) and CM-chitin conditioned medium (CM-chitin-sup), respectively (Scheme 1).

### Monolayer culture of C3H10T1/2 cells

The murine pluripotential cell line C3H10T1/2 (Health Science Research Resources Bank, Tokyo, Japan) was maintained as a monolayer culture in 25 or 75 cm<sup>2</sup> polystyrene tissue culture flasks (Becton Dickinson, Franklin Lakes, NJ) in DMEM supplemented with 10% FBS, 100  $\mu$ g/mL penicillin, and 100  $\mu$ g/mL streptomycin. The cells were incubated in a humidified incubator at 37°C and 5% CO<sub>2</sub>, and the culture medium was changed every 3 days.

C3H10T1/2 cells were seeded on 24-well culture plates at 10<sup>5</sup> cells/well and cultured with PBS (10% in medium), CM-chitin solution (1 mg/mL), CM-chitin gel suspension (1 mg/mL), or recombinant TGF- $\beta$ 1 (10 ng/mL, PeproTech, NJ) for 1–5 days. As a negative control, Triton X-100 was added to lyse the cells. The cell culture supernatants were collected every day and used in a cytotoxicity detection



**SCHEME 1.** A procedure for micromass culture. The conditioned media were prepared separately and applied to micromass culture.


assay with a lactate dehydrogenase (LDH) assay kit (Roche Applied Science, Mannheim, Germany) in accordance with manufacturer's procedure. The viability of the remaining cells was determined by 0.5% Trypan blue staining of cells treated with trypsin before they were scraped off the wells. Data are expressed as the mean  $\pm$  SE of three independent experiments. The LDH values and cell numbers of each group were analyzed for statistical significance using Welch's *t*-test. Total RNA was extracted from the cells at 7, 14, and 21 days, and the mRNA expression of growth factors and cartilage-related genes was analyzed using the reverse-transcriptase polymerase chain reaction (RT-PCR) as described previously.<sup>23</sup> The pairs of primer sequences used were as follows: For  $\beta$ -actin: 5'-ATGGATGACGATATCGCT-3' (sense) and 5'-ATGAGGTAGTCTGTCAGGT-3' (antisense). For TGF- $\beta$ 1: 5'-TACTATGCTAAAGAGGTACC-3' (sense) and 5'-TCCTGGTTCAGCCACTGCGC-3' (antisense). For Agr: 5'-AGTGATCTGGTCTGAATGACAGG-3' (sense) and 5'-AGAAGTTGT CAGCGTGGTTTGG-3' (antisense). For Col2a1: 5'-AGGGCAA CAGCAGGTTCACATAC-3' (sense) and 5'-TGCCACCAAAATT CCTGTCA-3' (antisense).

### Micromass culture

The micromass culture experiment was performed according to the protocol of Ahrens et al.<sup>32</sup> with slight modifications (Scheme 1). In brief, the C3H10T1/2 cells were trypsinized and resuspended in DMEM medium containing 10% FBS (basic medium) at a concentration of  $2 \times 10^7$  cells/mL, and 10  $\mu$ L of the suspension were transferred to a 48-well culture plate and allowed to adhere for 1 h at 37°C in 5% CO<sub>2</sub>. After the addition of 80  $\mu$ L of basic medium and 20  $\mu$ L of PBS, recombinant TGF- $\beta$ 1 (10 ng/mL), or one of the conditioned media (PBS-sup or CM-chitin-sup), the cells were cultured at 37°C in 5% CO<sub>2</sub>. The medium was changed every 4 days, and micromass tissues were collected at 7, 14, 21, and 28 days. For the TGF- $\beta$ 1 blocking experiment, anti-TGF- $\beta$ 1 mAb (R&D systems, Tokyo, Japan) were added in TGF- $\beta$ 1 medium or CM-chitin-sup at 10  $\mu$ g/mL and incubated for 1 h at room temperature before being used for the micromass culture. Each collected micromass tissue was used for mRNA expression analysis or histological staining.

### RNA extraction, cDNA synthesis, and PCR analysis

The total cellular RNA was extracted from the micromass tissue. RT-PCR was performed using the SideStep™ II QPCR cDNA Synthesis Kit (Stratagene, CA), and consecutive



**FIGURE 1.** Cytotoxic and proliferative assay for CM-chitin. (a) Cytotoxicity was evaluated with a lactate dehydrogenase (LDH) assay. Each LDH value represented the cytotoxicity of the respective reagent. The cells in the triton group were disrupted by triton reagent, so the LDH data of this group was used as a negative control. (b) Cell proliferation was determined by cell counting using a hemocytometer from days 1 to 5.

quantitative polymerase chain reactions (Q-PCR) were performed using SYBR Premix Ex Taq (Takara Bio, Shiga, Japan), according to the manufacturer's procedure. The sense and antisense primers for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), aggrecan (Agr), collagen-2a1 (Col2a1), cartilage oligomeric matrix protein (Comp), sex-determining region Y-box9 (Sox9), collagen-1a1 (Col1a1), and collagen-10a1 (Col10a1) were purchased from Takara Bio (Shiga, Japan). The amplified products were analyzed using the 7300 Real-Time PCR System (Applied Biosystems, CA), and the transcription level normalized to GAPDH was then calculated using the  $2^{-\Delta C_t}$  formula with reference to the undifferentiated mesenchymal stem cells.

### Histology and immunohistology

After 21 and 28 days, the collected micromass tissues were rinsed with PBS, fixed with 4% formaldehyde for 30 min, and washed twice with PBS. The tissues cultured in medium containing nothing, TGF- $\beta$ 1, PBS-sup, or CM-chitin-sup were collected on day 21 and stained with Alcian blue [pH 1.0, 1% Alcian blue 8 GX (Sigma-Aldrich, MO) in 0.1M HCl] overnight at 4°C and washed with PBS.

The tissues cultured in TGF- $\beta$ 1 or CM-chitin-sup until day 28 were embedded in paraffin, sectioned at 12  $\mu$ m using a microtome, and deparaffinized. The tissues cultured

in medium alone or with PBS-sup until day 28 were used directly for staining because they did not form 3D aggregates. One set of samples was stained by 0.05% Toluidine blue (pH7.0) before being washed with 99% EtOH. At the same time, the other set of samples was subjected to Protease K treatment and blocking treatment and incubated with Rabbit anti-mouse Collagen II polyclonal-antibody (ab21291, Abcam Japan, Tokyo, Japan) for 30 min. After being washed with Tris-buffered saline (TBS), the samples were incubated with the secondary antibody (EnVision<sup>TM</sup>+ Rabbit/HRP, DAKO Japan, Kyoto, Japan) before being washed with TBS. The samples were then stained with a substrate (DAB+ Liquid, DAKO Japan) for 1 min and washed with water, before being observed with an IX70 microscope (Olympus Medical Systems, Tokyo, Japan).

## RESULTS


### Effect of CM-chitin on a monolayer culture of C3H10T1/2 cells

First, we checked the endotoxin level of CM-chitin using the Endospecy<sup>®</sup> test. As a result, only a small amount of endotoxin was detected in gel-type CM-chitin at 100  $\mu$ g/mL.

We then investigated the effects of CM-chitin on cell viability, proliferation, and stimulation. The LDH values showed that neither CM-chitin nor CM-chitin gel affected the cell viability of C3H10T1/2 cells and that there was no significant difference between the two treatments [Fig. 1(a)]. The proliferation rates of the C3H10T1/2 cells treated with PBS, CM-chitin, and CM-chitin gel were similar during the culture period, while the proliferation rate of the cells treated with TGF- $\beta$ 1 was higher than those of the cells treated with other reagents, especially at 3–5 days of culturing [Fig. 1(b)]. The RNA expression of growth factors and two cartilage-related genes in the C3H10T1/2 cells in monolayer culture was not significantly different among the PBS, CM-chitin, CM-chitin gel, and TGF- $\beta$ 1-treated groups (Fig. 2).

### Expression of chondrogenic markers in micromass culture

To examine whether CM-chitin-sup, a conditioned medium from PEC stimulated by CM-chitin gel, promotes chondro-



**FIGURE 2.** Effect of CM-chitin on monolayer culture of C3H10T1/2 cells. The cells were cultured as a monolayer in the presence of the indicated stimuli for 21 days. mRNA was obtained from the cells in each well and subjected to RT-PCR for the detection of TGF- $\beta$ 1, transforming growth factor- $\beta$ 1; Agr, aggrecan; and Col2a1, collagen2a1.